NCT04980664

Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of China

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 2,000 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

China has the world's largest burden of hepatitis B virus (HBV) infection and will be a major contributor towards the global elimination of hepatitis B disease by 2030. One of the main issues in the management of patients with chronic HBV infection (CHB) is to maximize the individuals who need the treatment engaged and retained in care. However, our investigation revealed that 21.1% patients were treatment eligible but not treated based on Chinese 2019 CHB treatment guidelines, while only 213 (13.9%) patients were indicated-but-not-treated according to AASLD 2018 Hepatitis B guidance in a real-life cohort study. To maximize the individuals who need the treatment engaged and retained in care, integrated intervention strategies to address these treatment barriers are urgently needed. Therefore, we aim to propose a study to narrow the gap between in accordance with guidelines and consent to treat CHB population in EAST of China.

Conditions

• Chronic Hepatitis b

Interventions

Type	Name	Description
OTHER	Integrated intervention strategies	Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.

Timeline

• Start date: 2021-07-01
• Primary completion: 2022-12-31
• Completion: 2023-07-31
• First posted: 2021-07-28
• Last updated: 2021-07-28

Locations

4 sites across 1 country: China